Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Comparing the efficacy of rivoceranib and trifluridine/tipiracil administered individually as
monotherapies, as well as a rivocernib plus trifluridine/tipiracil combination therapy in the
treatment of mCRC that is unresponsive to traditional chemotherapies.